Life sciences startup Cora Therapeutics raises C$1m in seed VC

• Irongate Capital Advisors led the round
• Cora Therapeutics will use the funds to fuel the launch of DNA HALO in North America
• It will target medical professionals, medical imaging patients, air travel professionals, frequent fliers, military personnel and the health-conscious public

Toronto-based Cora Therapeutics, a life sciences startup focused on developing solutions for whole body health, has raised C$1 million in seed financing. Irongate Capital Advisors led the round.

To date, Cora has raised a total of C$1.8 million in seed funding.

Led by Dr. Kieran Murphy, Cora Therapeutics is the developer of DNA HALO, an advanced antioxidant formulation that helps to prevent cell damage from free radicals due to oxidative stress.

The startup will use the funds to fuel the launch of DNA HALO in North America. It will target medical professionals, medical imaging patients, air travel professionals, frequent fliers, military personnel and the health-conscious public.

Hamlet Yousef, a managing partner from Irongate, said in a statement, “Our mission is to direct capital to the highest-performing investments in the advanced technology arena, with a specific focus on dual-use innovations. We are excited about the broad applications for DNA HALO in the medical, consumer and military communities. We believe DNA Halo can help address the issues noted in a recent Pentagon study highlighting the increased risk of cancer among aviators and astronauts.”

Based in New York, Irongate Capital Advisors focuses on investing in innovations in aerospace, defense and intelligence, and national security.